| Methods |
2‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg during run‐in; 4‐week double‐blind treatment |
| Participants |
Enalapril 10 mg: n=36(24 males,12 females); mean age=53 years; baseline sitting SBP=152.9 mm Hg, DBP=100.5 mm Hg;
Lisinopril 10 mg: n=37(22 males,15 females); mean age=51 years; baseline sitting SBP=146.9 mm Hg, DBP=99.1 mm Hg;
Placebo: n=37(23 males,14 females); mean age=50 years; baseline sitting SBP=149.9 mm Hg, DBP=99.5 mm Hg |
| Interventions |
Enalapril 10 mg once daily;
Lisinopril 10 mg once daily;
Placebo;
administered between 8 AM and 9 AM |
| Outcomes |
Baseline adjusted mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SD not reported; calculated SD of change from N and change SE; BP data from Table II, p. 328; Jadad score=3; funding source= ICI Americas Inc. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
